Testing two medications together for melanoma that stopped responding to prior treatment

This trial is testing whether enfortumab vedotin combined with pembrolizumab can help people with advanced melanoma whose cancer has progressed despite previous treatment with immunotherapy. The study looks at two groups: people without a BRAF gene mutation, and people with a BRAF mutation who have also failed targeted therapy. Researchers believe this medication combination may work in two ways—by directly attacking cancer cells and by helping your immune system fight the cancer more effectively.

Many people with advanced melanoma see their cancer stop responding to standard immunotherapy, and doctors currently have limited options to help them. This trial exists to test whether this medication combination could provide a new treatment path for these patients.